Receptors, associations, and risk factor differences by breast cancer subtypes: Positive or negative?

Journal of the National Cancer Institute

Volumn 103, Issue 6, 2011, Pages 451-453

  Bernstein, Leslie ^a   Lacey Jr , James V ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; ORAL CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR; TRASTUZUMAB;

BREAST CANCER; BREAST FEEDING; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER SCREENING; EDITORIAL; EPIDEMIOLOGICAL DATA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE LOCUS; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MENARCHE; MENOPAUSE; NULLIPARA; ORAL CONTRACEPTION; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; TAXONOMY; TISSUE FIXATION; TREATMENT RESPONSE;

BREAST NEOPLASMS; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRODUCTIVE HISTORY; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79952833309     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr046     Document Type: Editorial

References (23)

1. Perou CM, Sorlie T, Eisen MP, et al. Molecular portraits of human breast tumors. Nature. 2000;406(6797):747-752.
2. Collett K, Stefansonn IM, Eide J, et al. A basal epithelial phenotype is more frequent in interval breast cancer compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1108-1112. (Pubitemid 40656455)
3. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15, pt 1): 4429-4434. (Pubitemid 47219710)
4. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25(43):5846-5853. (Pubitemid 44453440)
5. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26(26):4282-4288.
6. Phipps AI, Chlebowski RT, Prentice R, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 2011;103(6):470-477.
7. Habel LA, Stanford JL. Hormone receptors and breast cancer. Epidemiol Rev. 1993;15(1):209-219. (Pubitemid 23269084)
8. Althuis MD, Fergenbaum JH, Garcia-Closas M, et al. Etiology of hormone receptor-defned breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 2004;13(10):1558-1568. (Pubitemid 39331875)
9. Millikan R, Newman B, Tse C-K, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109(1):123-139. (Pubitemid 351538762)
10. Ma H, Wang Y, Sullivan-Halley J, et al. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res. 2010;70(2):575-587.
11. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21): 2492-2502. (Pubitemid 43854964)
12. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breasst cancer, the so-called triple-negative phenotype: A population-based study from the California Cancer Registry. Cancer. 2007;109(9):1721-1728. (Pubitemid 46668532)
13. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250-263.
14. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002;76(1):27-36. (Pubitemid 35178626)
15. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res. 2008;14(24):8000-8009.
16. Collins LC, Marotti JD, Baer HJ, Tamimi RM. Comparison of estrogen receptor results from pathology reports with results from central laboratory testing. J Natl Cancer Inst. 2008;100(3):218-221. (Pubitemid 351480544)
17. Ma H, Wang Y, Sullivan-Halley J, et al. Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports? Cancer Epidemiol Biomarkers Prev. 2009;18(8):2214-2220.
18. Shah S, Chen B. Testing for HER2 in breast cancer: a continuing evolution. Path Res Internatl. 2011. Article ID 903202.
19. Sauter G, Lee J, Bartlett JMS, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodo-logic considerations. J Clin Oncol. 2009;27(8):1323-1333.
20. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2006; 24(19):3032-3038. (Pubitemid 46638937)
21. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005;11(18):6598-6607. (Pubitemid 41339000)
22. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94(11):852-854. (Pubitemid 34705057)
23. Schmidt C. How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear. J Natl Cancer Inst. 2011;103(2): 87-89.